CD274 and neoplasm: In light of the experience of other solid tumors and preclinical trials of immunotherapy for OC, these markers mainly include tumor mutation load, PD-L1, tumor infiltrating lymphocytes, homologous recombination defects, and intratumor neoantigen heterogeneity (8).